antithymocyte globulin

Exploring Low-Dose Antithymocyte Globulin Therapy in Type 1 Diabetes: Real-World Insights Using Modified Quantitative Response of C-Peptide

By MedXY 07/14/2026

This article examines real-world data on low-dose antithymocyte globulin in type 1 diabetes, assessing beta-cell function via a novel C-peptide modified quantitative response (mQR). Findings suggest feasibility, safety, and potential clinical benefit in preserving endogenous insulin secretion.

Hematology-Oncology news

Model-Based ATG Dosing Successfully Accelerates CD4+ Reconstitution in CD34+ Selected Allogeneic HCT

By MedXY 01/13/2026

A Phase 2 study demonstrates that pharmacokinetic model-based ATG dosing significantly enhances CD4+ T-cell reconstitution in patients undergoing CD34+ selected hematopoietic cell transplantation, reaching primary endpoints in 70% of participants and offering a path toward safer, more effective transplant outcomes.

Diabetes & Endocrinology Specialties

Optimizing Antithymocyte Globulin Dose for Preserving Beta-Cell Function in Recent-Onset Type 1 Diabetes: Insights from the MELD-ATG Trial

By MedXY 10/11/2025

The MELD-ATG phase 2 trial identifies low-dose antithymocyte globulin as an effective and safe intervention to reduce beta-cell loss in young people with recent-onset type 1 diabetes, highlighting a potential disease-modifying therapy.